FDA approves Boehringer's propellant-free COPD meter-dose inhaler medicine
This article was originally published in Scrip
Executive Summary
With Boehringer Ingelheim's chronic obstructive pulmonary disease (COPD) drug Combivent (ipratropium bromide and albuterol sulfate) due to exit the US market by 31 December 2013 because it uses chlorofluorocarbons (CFCs) – a chemical compound found to deplete the ozone layer – the US FDA on 7 October approved what it said was a "suitable alternative".